Discrimination of acute graft-versus-host disease from infections by enumeration of peripheral blood interferon-γ spot-forming cells

Transplantation

Volumn 81, Issue 4, 2006, Pages 632-635

  Hirayama, Masahiro ^a   Azuma, Eiichi ^a   Kumamoto, Tadashi ^a   Iwamoto, Shotaro ^a   Nashida, Yuji ^a   Araki, Mariko ^a   Yamada, Hiroshi ^a   Dida, Francis ^a   Tamaki, Shigehisa ^b   Kawakami, Keiki ^c   Kageyama, Shinichi ^a   Nakano, Takashi ^d   Yamamoto, Hatsumi ^e   Komada, Yoshihiro ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ISE RED CROSS HOSPITAL   (Japan)

^c SUZUKA GENERAL HOSPITAL   (Japan)

^d MIE NATIONAL HOSPITAL   (Japan)

^e National Hospital Organization Mie Chuo Medical Center   (Japan)

Author keywords

ELISPOT; Graft versus host disease; Hematopoietic stem cell transplantation; Interferon

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; BLOOD; CHILD; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNE STATUS; INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; VIRUS INFECTION;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; INFANT; INFECTION; INTERFERON TYPE II; MALE; STEM CELL TRANSPLANTATION;

EID: 33644611023     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000200303.00813.a8     Document Type: Article

References (20)

1. Hirayama M, Azuma E, Kumamoto T, et al. Prediction of Acute Graft-Versus-Host Disease and Detection of Distinct End-Organ Targets by Enumeration of Peripheral Blood Cytokine Spot-Forming Cells. Transplantation 2005; 80(1): 58.
2. Mitchell AE, Derrington P, Turner P, et al. Gram-negative bacteraemia (GNB) after 428 unrelated donor bone marrow transplants (UD-BMT): risk factors, prophylaxis, therapy and outcome. Bone Marrow Transplant 2004; 33(3): 303.
3. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107(12): 1581.
4. Krenger W, Ferrara JL. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res 1996; 15(1): 50.
5. Mengoli C, Cusinato R, Biasolo MA, et al. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection. J Med Virol 2004; 74(1): 78.
6. Walker SA, Rogers TR, Riches PG, et al. Value of serum C-reactive protein measurement in the management of bone marrow transplant recipients. Part I: Early transplant period. J Clin Pathol 1984; 37(9): 1018.
7. Obayashi T, Yoshida M, Mori T, et al. Plasma (1->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345(8941): 17.
8. Woo PC, Wong SS, Lum PN, et al. Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients. Lancet 2001; 357(9257): 675.
9. Liem LM, van Lopik T, van Nieuwenhuijze AE, et al. Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections. Blood 1998; 91(4): 1464.
10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18(4): 295.
11. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355(9220): 2032.
12. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83(7): 1971.
13. Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66(10): 1330.
14. Morishima Y, Morishita Y, Tanimoto M, et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood 1989; 74(6): 2252.
15. Sakamaki H, Yuasa K, Goto H, et al. Comparison of cytomegalovirus (CMV) antigenemia and CMV in bronchoalveolar lavage fluid for diagnosis of CMV pulmonary infection after bone marrow transplantation. Bone Marrow Transplant 1997; 20(2): 143.
16. Rentenaar RJ, Heydendael VM, Diepen FN, et al. Systemic Treatment with Either Cyclosporin A or Methotrexate Does Not Influence the T Helper 1/t Helper 2 Balance in Psoriatic Patients. J Clin Immunol 2004; 24(4): 361.
17. Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Investig Med 2001; 49(5): 442.
18. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100(13): 4521.
19. Lacey SF, Martinez J, Gallez-Hawkins G, et al. Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. J Infect Dis 2005; 191(6): 977.
20. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 1990; 5(4): 209.